GP-39 Activators
GP-39, also known as chitinase 3-like protein 1 (CHI3L1), is a glycoprotein belonging to the chitinase protein family. It plays a significant role in various physiological processes, including inflammation, tissue remodeling, and immune response modulation. GP-39 is primarily expressed and secreted by activated macrophages, neutrophils, and other cell types in response to inflammatory stimuli. Its expression is often upregulated in pathological conditions such as asthma, rheumatoid arthritis, and cancer, indicating its involvement in disease pathogenesis.
Activation of GP-39 involves complex signaling pathways triggered by inflammatory mediators and cytokines. Upon stimulation, pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) induce the activation of transcription factors such as nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1). These transcription factors then bind to the promoter region of the GP-39 gene, leading to its transcriptional upregulation. Additionally, signaling cascades involving mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K)/Akt pathways are implicated in GP-39 activation. These pathways contribute to the phosphorylation and activation of downstream effectors that ultimately regulate GP-39 expression and secretion. Moreover, GP-39 activation is tightly regulated at the post-translational level through processes such as glycosylation and proteolytic cleavage, further modulating its biological activity. Understanding the intricate mechanisms governing GP-39 activation is essential for elucidating its role in inflammatory diseases and identifying targets for intervention.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMP-activated protein kinase (AMPK) activator, directly influences GP-39 by activating AMPK, a pathway that intersects with GP-39 signaling, leading to modulation of GP-39 expression or activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Peroxisome proliferator-activated receptor gamma (PPARγ) agonist, potentially activates GP-39 by stimulating PPARγ-mediated transcriptional regulation, leading to enhanced GP-39 expression or activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Sirtuin 1 (SIRT1) activator, indirectly activates GP-39 through SIRT1-mediated deacetylation, impacting downstream targets linked to GP-39 expression or activity. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Activates the insulin receptor and downstream PI3K/Akt pathway, influencing GP-39 by modulating cellular processes linked to GP-39 expression or activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Calcium ionophore, indirectly activates GP-39 through calcium signaling pathways, which may intersect with signaling cascades related to GP-39 expression or activity. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
Peroxisome proliferator-activated receptor delta (PPARδ) agonist, potentially activates GP-39 by stimulating PPARδ-mediated transcriptional regulation, leading to enhanced GP-39 expression or activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator, activates cAMP-dependent pathways, indirectly influencing GP-39 through downstream signaling cascades linked to cAMP, leading to modulation of GP-39 expression or activity. | ||||||
β-Nicotinamide mononucleotide | 1094-61-7 | sc-212376 sc-212376A sc-212376B sc-212376C sc-212376D | 25 mg 100 mg 1 g 2 g 5 g | $110.00 $150.00 $220.00 $300.00 $600.00 | 4 | |
NAD+ precursor, activates sirtuins and downstream signaling pathways, indirectly influencing GP-39 through SIRT-mediated pathways that intersect with GP-39 signaling, leading to modulation of GP-39 expression or activity. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
Peroxisome proliferator-activated receptor alpha (PPARα) agonist, potentially activates GP-39 by stimulating PPARα-mediated transcriptional regulation, leading to enhanced GP-39 expression or activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Cell-permeable cAMP analog, activates cAMP-dependent pathways, indirectly influencing GP-39 through downstream signaling cascades linked to cAMP, leading to modulation of GP-39 expression or activity. | ||||||